On April 23, 2021, the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) recommended that use of Johnson & Johnson’s Janssen COVID-19 vaccine (also known as the J&J vaccine) resume in the U.S. This update comes after a temporary pause went into effect due to health and safety concerns.
In response and following the publication of CDC’s Morbidity and Mortality Weekly Report, the Department of Defense (DoD) resumed its use of the J&J vaccine on Wednesday, April 28, 2021.
